BridgeBio Pharma vs Jazz Pharmaceuticals
BridgeBio Pharma (BBIO), health care, and Jazz Pharmaceuticals (JAZZ), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Jazz Pharmaceuticals is worth $15.5B on the stock market and BridgeBio Pharma $15B: Jazz Pharmaceuticals is valued at 3% more. BridgeBio Pharma's operating margin in its latest fiscal year was -104% and Jazz Pharmaceuticals's -10.1%. Over the past year BridgeBio Pharma's share price has moved +17.9% and Jazz Pharmaceuticals's +32.8%.
Key facts
- BridgeBio Pharma market value
- $15B
- Jazz Pharmaceuticals market value
- $15.5B
- Jazz Pharmaceuticals P/E
- 71.2
- BridgeBio Pharma revenue
- $502.1MFY to 2025-12-31
- Jazz Pharmaceuticals revenue
- $4.3BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | BridgeBio Pharma | Jazz Pharmaceuticals |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $15Blower | $15.5Bhigher |
| Revenue | $502.1Mlower | $4.3Bhigher |
| Earnings | -$732.9Mlower | -$356.1Mhigher |
| Employees | 1,081lower | 2,890higher |
| Total assets | $936Mlower | $11.7Bhigher |
| Valuation | ||
| P/E | — | 71.2 |
| P/S | 29.8higher | 3.6lower |
| P/B | — | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | -104%lower | -10.1%higher |
| Balance sheet | ||
| Net assets | -$2.1Blower | $4.3Bhigher |
| Total liabilities | $3Blower | $7.3Bhigher |
| Total debt | $2Blower | $5.4Bhigher |
| Cash on hand | $570.1Mlower | $1.4Bhigher |
| Price change | ||
| Today | -0.72%lower | +0.39%higher |
| 1 year | +17.9%lower | +32.8%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Percentages are each holding's share of that investor's reported portfolio (under "Both": BridgeBio Pharma / Jazz Pharmaceuticals). Who owns BBIO · Who owns JAZZ
More on BridgeBio Pharma
Further comparisons
BridgeBio Pharma against its closest peers
Jazz Pharmaceuticals against its closest peers
Learn
Questions and answers
Which is bigger, BridgeBio Pharma or Jazz Pharmaceuticals?
By market value, Jazz Pharmaceuticals is the larger: $15.5B against $15B for BridgeBio Pharma. By revenue in its latest fiscal year, Jazz Pharmaceuticals is the larger: $4.3B against $502.1M for BridgeBio Pharma.
Which has the higher operating margin?
Jazz Pharmaceuticals: -10.1%, against -104% for BridgeBio Pharma. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has more debt?
Jazz Pharmaceuticals: $5.4B, against $2B for BridgeBio Pharma. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both BridgeBio Pharma and Jazz Pharmaceuticals?
In their latest 13F filings, Ken Griffin holds both.
Cite this page
Funkfolio, “BridgeBio Pharma vs Jazz Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/bbio-vs-jazz
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.